Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to dolutegravir + rilpivirine in virologically suppressed HIV-1-infected adults
2014-005148-16Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dolutegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL. Started Apr 2015; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-005148-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005148-16.